Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Lionel AC, et al. Among authors: nair r. Leuk Lymphoma. 2024 May;65(5):669-673. doi: 10.1080/10428194.2024.2304622. Epub 2024 Jan 22. Leuk Lymphoma. 2024. PMID: 38248629 No abstract available.
Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function.
Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Gunther JR, et al. Among authors: nair r. Leuk Lymphoma. 2020 Jan;61(1):171-175. doi: 10.1080/10428194.2019.1644333. Epub 2019 Aug 2. Leuk Lymphoma. 2020. PMID: 31373240 No abstract available.
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Strati P, et al. Among authors: nair r. Leuk Lymphoma. 2020 Jun;61(6):1380-1387. doi: 10.1080/10428194.2020.1716221. Epub 2020 Jan 23. Leuk Lymphoma. 2020. PMID: 31971032
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Jain P, et al. Among authors: nair r. Blood Adv. 2020 Mar 24;4(6):1038-1050. doi: 10.1182/bloodadvances.2019001396. Blood Adv. 2020. PMID: 32191807 Free PMC article.
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Zhao S, et al. Among authors: nair r. Am J Hematol. 2020 Jun;95(6):623-629. doi: 10.1002/ajh.25796. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32239765 Free article. Clinical Trial.
Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission.
Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Glober G, et al. Among authors: nair r. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):533-541. doi: 10.1016/j.clml.2020.02.008. Epub 2020 Feb 20. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32291233 Free PMC article.
CAR T-Cells.
Nair R, Westin J. Nair R, et al. Adv Exp Med Biol. 2020;1244:215-233. doi: 10.1007/978-3-030-41008-7_10. Adv Exp Med Biol. 2020. PMID: 32301017 Review.
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Pinnix CC, et al. Among authors: nair r. Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837. Blood Adv. 2020. PMID: 32589728 Free PMC article.
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Strati P, et al. Among authors: nair r. Blood Adv. 2020 Jul 14;4(13):3123-3127. doi: 10.1182/bloodadvances.2020002328. Blood Adv. 2020. PMID: 32645136 Free PMC article. No abstract available.
2,704 results